Work

Clinical impact of DPYD genotyping and dose adjustment in candidates for fluoropyrimidine treatment

Year: 2024

Type: article

Abstract: Fluoropyrimidines (5-fluorouracil, capecitabine, and tegafur) are widely used in the treatment of different malignant tumors, including cancer of the stomach, bowel, pancreas, esophagus, and breast; and squamous cell carcinoma of the head and neck [1–6]. More than two million people per year are diagnosed with cancers that are treated with fluoropyrimidines, usually in combination with other antineoplastic agents [1–4,7].

Source: Heliyon

DOI: 10.1016/j.heliyon.2024.e40808

Authors: Ana Hernández-Guío, Miguel Ángel Calleja-Hernández, Andrés Corno-Caparrós, Marta Zayas-Soriano, Mª Ángeles Bernabéu-Martínez, Fernando Gutiérrez-Nicolás

Institutions: Hospital Universitari Sant Joan D'Alacant, Hospital Universitario Virgen Macarena, Universitat de Miguel Hernández d'Elx

Language: English

Topic: Pharmacogenetics and Drug Metabolism

Subfield: Pharmacology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,100